Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd.

Sichuan Kelan Pharmaceutical Research Institute Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceuticals Co., Ltd.

Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd.

Lichun Wang

Jingyi Wang

Jiaqiang Cai

Qiang Tian

Hong Zeng

Hongmei Song

Tongtong Xue

Liang Xiao

Shuai Song

Mingliang Zhao

Dong Zhao

Dong Long

Likai Yang

Hanwen Deng

Donghai Su

Zhengxing Su

Yongyong Wu

Fengying Shan

Jing Wang

Dengnian Liu

Wei Zhong

Yao Liu

Guoqing Zhong

Chengxi Yang

Zujian Tang

Tianming Wang

Rongrong Long

Haitao Huang

Zhongmin Maxwell Wang

Yu Xia

Baiyong Li

Wei Liu

Qijun Ye

Chaolei Wang

Wei Qi

Baolei Zhang

Yufeng Liang

Yan Qing

Xiaofan Duan

Jiawang Zhu

Yujun Wang

Xiaoxi Yuan

Kexing Wang

Zhiquan Song

Nan Yu

Yan Feng

Hua Deng

Liping Liu

Xin Zhou

Yuting Tan

Jing Zhou

Jianhua Ge

Yinong Xie

Zejin You

Zhiwen Deng

Jun Zhu

Ao Wang

Qiang Li

Gang Chen

Zhenwei Miao

Si Ruo Chen

Hong Zhang

Tong Zhu

Ying Wang

Yuncheng Zheng

Qiang Zhang

Jinming Liu

Ping Zhang

Ping Liu

Hu Long

Yitao Zhang

Yongjia Hao

Jiangfeng Zhou

Fulu Zhao

Jianfeng Han

Hong Ye

Xiaoda Niu

Shidong Yi

Gang Liu

Wenjia Li

Zheng Gong

Donghong Li

Daibiao Xiao

Shaohua Li

Xunwei Wu

Jiangjiang Hu

Yamin Cui

Hao Hu

Weibiao Han

Youqiang Li

Xing Chen

Guangchao Zhang

Shuangshuang Duan

Yan Hu

Wei Yin

Long Yang

Lei Wu

Zengying Han

Fengchun Chen

Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

Use of anti-HER2 antibody-drug conjugate in cancer treatment

Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Bioactive molecule conjugate, preparation method and use thereof

Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Albumin pharmaceutical composition and preparation method therefor

Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,

Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof

The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.

Isoxazole derivative, preparation method therefor, and use thereof

The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune response, or are used for preventing and/or treating tumors, infections or autoimmune diseases.

Anti-LAG-3 antibody and use thereof

Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.

Tetrahydroisoquinoline derivatives, preparation process and use thereof

Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.

Solid form of dihydropyrimidine compound and preparation method therefor and use thereof

Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.

Recombinant bispecific antibodies to PD-L1 and CTLA-4

The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.

Docetaxel albumin nanoparticle pharmaceutical composition, preparation method therefor and use thereof

The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

Aromatic compound, pharmaceutical composition and use thereof

Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like. 

Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof

A pharmaceutical composition comprising a 4'-thionucleoside phosphamide derivative or a pharmaceutically acceptable salt, ester, hydrate, solvate, and isomer thereof, any crystalline form thereof or racemate, metabolite, or a combination of a mixture thereof with other drugs, and a method and use thereof for disease treatment and/or prevention.

Pharmaceutical composition for tumor treatment or prevention, method, and use thereof

Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3&#x3b6; molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Cytotoxin and conjugate, uses of same and preparation method therefor

Growing community of inventors

Chengdu, China

Lichun Wang